Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Other financing activities (2016 - 2019)

Sunshine Biopharma (SBFM) has disclosed Other financing activities for 7 consecutive years, with $7590.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Other financing activities fell 98.88% year-over-year to $7590.0, compared with a TTM value of $7590.0 through Dec 2020, changed N/A, and an annual FY2018 reading of $676100.0, up 58.19% over the prior year.
  • Other financing activities was $7590.0 for Q4 2019 at Sunshine Biopharma, up from -$7590.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $676100.0 in Q4 2018 and bottomed at -$491986.0 in Q2 2018.
  • Average Other financing activities over 4 years is $150483.3, with a median of $89200.0 recorded in 2016.
  • Peak annual rise in Other financing activities hit 1292.42% in 2018, while the deepest fall reached 727.53% in 2018.
  • Year by year, Other financing activities stood at $282800.0 in 2016, then crashed by 120.05% to -$56700.0 in 2017, then skyrocketed by 1292.42% to $676100.0 in 2018, then crashed by 98.88% to $7590.0 in 2019.
  • Business Quant data shows Other financing activities for SBFM at $7590.0 in Q4 2019, -$7590.0 in Q2 2019, and $676100.0 in Q4 2018.